Navigation Links
Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target

SEATTLE, Jan. 6 /PRNewswire/ -- Omeros Corporation today announced that The Michael J. Fox Foundation has awarded it a $465,000 grant against milestones to support the Company's collaboration with The Parkinson's Institute to evaluate Omeros' recent discovery of a new target for the treatment of Parkinson's disease. Located in regions of the brain responsible for Parkinson's disease, Omeros is the first to link its novel target to the treatment of any movement disorder, including Parkinson's disease and Restless Legs Syndrome. Omeros will continue to retain all of its rights associated with this novel target.

"We are pleased that The Michael J. Fox Foundation is joining our efforts to develop a novel treatment for Parkinson's disease," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "The Foundation is a well-recognized leader in Parkinson's research, and its support will be key to testing the potential of our proprietary approach for treating patients living with the disease."

Under Omeros' collaboration with The Parkinson's Institute, preclinical studies using a widely accepted and highly predictive model for the symptomatic treatment of Parkinson's disease are being conducted on one or more compounds that block Omeros' proprietary target. Omeros' earlier studies conducted at Emory University by Gary W. Miller, Ph.D. in a similar model showed that compounds blocking this novel target were as effective as levodopa, or L-DOPA, at doses 50- to 100-times lower than those of L-DOPA. L-DOPA has been the standard treatment for Parkinson's disease for nearly 40 years but is associated with profound side effects including dyskinesias, hallucinations, sleep disorders and cognitive impairment. Omeros plans to explore the clinical utility of one or more of the compounds currently under evaluation both singly and in conjunction with L-DOPA.

Parkinson's disease, a degenerative disorder of the central nervous system, often impairs motor skills, speech and other functions. It is estimated that approximately 1.5 million people in the U.S. suffer from the disease, and an estimated 60,000 new cases are reported each year.

Restless Legs Syndrome(RLS), also a neurological disorder, is characterized by irritating sensations in the legs and an uncontrollable urge to move them when at rest. If left untreated, it can cause exhaustion and daytime fatigue. RLS is estimated to affect as many as 12 million Americans, but the incidence could be significantly higher due to under- or misdiagnosis.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $130 million in research to date, either directly or through partnerships. For more information, please visit the Foundation's Web site at

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
2. Omeros and BlueCrest Announce $20 Million Debt Facility
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros Appoints David A. Mann to its Board of Directors
5. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
6. Probiotic Delivery Technology Awarded Third International Patent
7. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
8. China Medicine Corporation Awarded GSP Certification
9. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
10. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
11. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):